Replies to post #425716 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

While your equation is correct dennisdave

MC = SP x OS

Market Cap alone does not dictate share price.
This is not true
SP = OS / MC
where an increase in Overall Shares immediately reduce the share price.
In a fair market SP to a large extent is highly dependent on what the market believes the revenue growth of the company will be in the next 6-12 months . . . the projected P/E ratio.
https://www.gliocure.com/en/patients/glioblastoma/

The number of new cases of glioblastomas per year can thus be estimated at around 250,000 worldwide, with an over-incidence in the Caucasian populations and a slight increase anticipated in the years to come due to the aging of the population.

250,000 cases x $250,000 per treatment = $62.5 billion in GBM revenue alone.
Now treatments will be rolling out for US, Canada and Europe first and since the treatment is personalized, made for each patient, volume production capability will be constrained by the number of stations able to produce the treatment but over time demand will push revenue up and up and up. This is only DCVAX-L and not DCVAX-Direct which can be used to treat all solid tumor cancers and since DCVAX does not have the toxic side effects of chemo it will probably become SOC demanded by patents vs chemo over time.

Anyway the price drop end of the day Friday was big money thugs/goons manipulating the price and not simply due to investors exercising warrants